Primary mediastinal large B-cell lymphoma is a rare but highly treatable form of cancer that mainly affects young adults, particularly women, and develops as a mass in the chest area. Although treatment can be challenging, modern approaches aim to maximize cure rates while minimizing long-term side effects, and researchers continue to explore innovative therapies that may offer new hope for patients.

Modern approaches to controlling primary mediastinal large B-cell lymphoma

Primary mediastinal large B-cell lymphoma, often abbreviated as PMBCL, presents unique challenges that require carefully planned treatment strategies. The main goal of treatment is to eliminate the cancer completely while preserving the patient’s quality of life, especially since this condition typically affects young people who have many years ahead of them. Treatment decisions depend heavily on the stage of disease, the size of the tumor mass in the chest, and the patient’s overall health and ability to tolerate intensive therapy.^[2]

Medical societies and cancer centers worldwide have established standard treatment protocols based on years of research and clinical experience. These protocols have evolved significantly over the past decades, moving from approaches that heavily relied on radiation therapy to more sophisticated strategies that use combinations of powerful medications. At the same time, researchers are actively investigating new treatments through clinical trials, testing innovative therapies that target specific features of this cancer’s biology. This dual approach—using proven treatments while exploring new possibilities—offers patients both immediate care and future hope.^[10]

The treatment landscape for PMBCL has improved dramatically in recent years, with survival rates now exceeding 80% in most studies. However, because this cancer occurs primarily in adolescents and young adults, doctors must consider not just immediate cure rates but also the long-term effects of treatment. Young women, who make up the majority of PMBCL patients, face particular concerns about fertility preservation, the risk of secondary cancers from radiation, and potential heart damage from certain chemotherapy drugs. These considerations shape every treatment decision, pushing the medical community toward approaches that are both effective and mindful of patients’ futures.^[8]

Standard treatment protocols and their components

The cornerstone of PMBCL treatment involves chemotherapy, which uses powerful drugs to kill cancer cells throughout the body. Chemotherapy for PMBCL is never given as a single drug; instead, doctors use combinations of several medications that work together to attack cancer cells in different ways. The most commonly used regimen is called R-CHOP, which combines five different agents: rituximab, cyclophosphamide, doxorubicin (also known as hydroxydaunorubicin), vincristine (sold under the brand name Oncovin), and prednisone. Each of these drugs has a specific role in fighting the cancer, and together they create a powerful effect that is greater than any single drug could achieve.^[3]

Rituximab is particularly important in this combination. It is a type of medication called a monoclonal antibody, which means it is designed to recognize and attach to a specific protein called CD20 that appears on the surface of B cells, including the cancerous B cells in PMBCL. Once rituximab attaches to these cells, it marks them for destruction by the body’s immune system. The addition of rituximab to traditional chemotherapy has significantly improved outcomes for patients with PMBCL, transforming it from a challenging disease to one with excellent cure rates in many cases.^[4]

An alternative and increasingly popular approach is DA-EPOCH-R, which stands for dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, plus rituximab. This regimen is more intensive than R-CHOP, delivering drugs through continuous infusion over several days rather than quick injections. The “dose-adjusted” part means that doctors modify the amounts of medication based on how well the patient’s blood counts recover between treatment cycles. This personalized dosing approach aims to give each patient the maximum effective dose they can tolerate. Studies have shown that DA-EPOCH-R may allow many patients to avoid radiation therapy to the chest, which is particularly important for young women who face increased risk of breast cancer from mediastinal radiation.^[10]

Treatment typically consists of six cycles of chemotherapy, with each cycle lasting either two or three weeks depending on the specific regimen used. This means the entire course of treatment usually spans four to six months. During this time, patients receive their medications either in a hospital’s infusion center or sometimes as inpatients if complications arise. Between cycles, patients undergo blood tests to ensure their blood cell counts have recovered sufficiently to receive the next round of treatment. If counts are too low, treatment may be delayed to allow the bone marrow more time to produce new healthy blood cells.^[2]

Regarding radiation therapy, there is ongoing debate about when and if it should be used in PMBCL. Historically, radiation to the mediastinum (the area between the lungs where PMBCL develops) was considered standard practice after chemotherapy. However, modern approaches increasingly question this practice, especially with the use of more intensive chemotherapy regimens like DA-EPOCH-R. Radiation therapy involves directing high-energy beams at the tumor area to kill any remaining cancer cells. While effective, radiation to the chest in young women significantly increases the risk of breast cancer later in life, and it can also cause heart problems and lung scarring. Current practice often involves using imaging tests, particularly PET-CT scans, after chemotherapy to determine if any active cancer remains. If scans show no evidence of active disease, many doctors now choose to omit radiation entirely.^[4]

However, if there is still evidence of disease after chemotherapy, radiation may be recommended. Some patients also receive radiation if they have particularly large tumors at diagnosis or if the tumor invades surrounding structures. The radiation field is carefully planned to minimize exposure to healthy tissues, especially the heart, lungs, and breast tissue in women. Modern radiation techniques allow for more precise targeting than was possible in the past, reducing but not eliminating the risk of long-term complications.^[16]

Standard chemotherapy regimens cause a range of side effects that patients should anticipate. Hair loss is common with both R-CHOP and DA-EPOCH-R, though hair typically grows back after treatment ends. Nausea and vomiting can occur, but modern anti-nausea medications have made these symptoms much more manageable than in the past. Fatigue is nearly universal, as chemotherapy affects not just cancer cells but also rapidly dividing healthy cells throughout the body. Patients often experience drops in their blood cell counts, leading to anemia (low red blood cells causing tiredness), neutropenia (low white blood cells increasing infection risk), and thrombocytopenia (low platelets increasing bleeding risk).^[2]

Some side effects are specific to particular drugs in the regimen. Doxorubicin can affect the heart, so doctors monitor heart function with echocardiograms or similar tests before, during, and after treatment. Vincristine can cause nerve damage, leading to numbness, tingling, or pain in the hands and feet—a condition called peripheral neuropathy. Cyclophosphamide can irritate the bladder and may affect fertility, which is why fertility preservation options are discussed before treatment begins. Steroids like prednisone can cause mood changes, difficulty sleeping, increased appetite, elevated blood sugar, and increased infection risk. Most side effects resolve after treatment ends, but some, like peripheral neuropathy or heart damage, may be long-lasting.^[3]

Innovative therapies in clinical trials

For patients whose PMBCL does not respond to initial treatment or who experience relapse after achieving remission, the situation becomes more challenging, but several promising therapies are now being tested in clinical trials. The standard approach for relapsed or refractory PMBCL has traditionally involved high-dose chemotherapy followed by autologous stem cell transplantation, where a patient’s own stem cells are collected, frozen, and then returned after intensive chemotherapy. However, this approach has proven less successful in PMBCL than in some other lymphomas, driving the search for better alternatives.^[10]

One of the most exciting developments involves drugs called immune checkpoint inhibitors, particularly those targeting a protein called PD-1 (programmed death-1). PMBCL cells have a clever survival strategy: they produce high levels of proteins called PD-L1 and PD-L2 on their surface, which act like “off switches” for the immune system. When these proteins interact with PD-1 on immune cells, they essentially tell the immune system to leave the cancer cells alone. Checkpoint inhibitors block this interaction, removing the brakes from the immune system and allowing it to attack the cancer cells.^[10]

Pembrolizumab (sold under the brand name Keytruda) is one such checkpoint inhibitor that has shown particularly promising results in PMBCL. This drug is a type of immunotherapy that essentially teaches the patient’s own immune system to recognize and destroy cancer cells. Clinical trials have demonstrated that pembrolizumab can produce high response rates in patients with relapsed or refractory PMBCL, and importantly, these responses can be durable, meaning they last for extended periods. The drug is typically given as an intravenous infusion every few weeks and is generally better tolerated than traditional chemotherapy, though it can cause side effects related to an overactive immune system, such as inflammation of the lungs, intestines, or other organs.^[4]

Another immunotherapy approach involves CAR T-cell therapy, a highly sophisticated treatment that represents a major technological advance in cancer care. In this treatment, a patient’s own T cells (a type of immune cell) are removed from their blood through a process similar to blood donation. These cells are then sent to a specialized laboratory where they are genetically modified to produce special receptors called chimeric antigen receptors (CARs) on their surface. These receptors are designed to recognize and attach to CD19, a protein found on B cells, including PMBCL cells. Once the cells are modified, they are grown to large numbers in the laboratory and then infused back into the patient, where they act as “living drugs” that hunt down and destroy cancer cells.^[4]

Two specific CAR T-cell products have shown effectiveness in PMBCL: axicabtagene ciloleucel (marketed as Yescarta) and lisocabtagene maraleucel. These therapies are typically considered for patients who have already tried at least two other treatment approaches without success. The response rates seen with CAR T-cell therapy in PMBCL have been encouraging, with many patients achieving complete remission. However, these treatments can cause significant side effects, including cytokine release syndrome (a condition where the modified immune cells release large amounts of inflammatory molecules into the bloodstream, causing fever, low blood pressure, and other symptoms) and neurological effects such as confusion or difficulty speaking. Most of these side effects are manageable with appropriate medications and monitoring.^[10]

Clinical trials are also exploring bispecific antibodies, a newer type of immunotherapy that represents an innovative approach to cancer treatment. These engineered proteins have two different binding sites: one that attaches to CD20 (a protein on the surface of B cells including PMBCL cells) and another that attaches to CD3 (a protein on T cells). By connecting these two cell types, bispecific antibodies physically bring cancer cells and immune cells together, enabling the immune system to destroy the cancer. Two bispecific antibodies being studied in PMBCL are epcoritamab (Epkinly) and glofitamab (Columvi). These medications may be offered to patients after two or more previous treatment approaches, particularly if CAR T-cell therapy has already been tried or if the patient is not a suitable candidate for CAR T-cell therapy.^[4]

Researchers are also investigating the role of brentuximab vedotin in PMBCL treatment. This drug is an antibody-drug conjugate, meaning it consists of an antibody linked to a chemotherapy drug. The antibody portion targets CD30, a protein that appears on the surface of some PMBCL cells (though usually in a patchy pattern rather than uniformly). When used alone, brentuximab vedotin has shown limited activity in PMBCL. However, when combined with checkpoint inhibitors like pembrolizumab, the combination appears more effective than either drug alone. This combination approach is being tested in clinical trials, with early results suggesting higher response rates than would be expected from checkpoint inhibitors alone.^[10]

Some clinical trials are exploring whether dose-intensive chemotherapy regimens can improve outcomes in the frontline setting. These regimens include approaches like R-ACVBP (rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone), which delivers chemotherapy in a more compressed and intensive schedule than standard R-CHOP. A systematic review and meta-analysis of over 4,000 patients found that dose-intensive approaches demonstrated an overall survival benefit compared to standard R-CHOP, with an 8% improvement in overall survival. Importantly, patients receiving dose-intensive regimens required radiation therapy much less frequently—only 22% compared to 55% in the standard treatment group—suggesting that more intensive chemotherapy might allow more patients to avoid the long-term risks of radiation.^[12]

Many clinical trials are conducted at major cancer centers in the United States, Europe, and other regions around the world. Eligibility for these trials typically depends on factors such as whether the patient has received previous treatment, how well their organs are functioning, and the specific characteristics of their cancer. Patients interested in clinical trials should discuss the options with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks. Some trials may require travel to specialized centers, while others may be available at more local facilities through cooperative networks.^[16]

The phases of clinical trials serve different purposes in evaluating new treatments. Phase I trials primarily assess safety, determining what dose of a new drug can be given safely and what side effects occur. Phase II trials evaluate whether the treatment works against a specific cancer type and continue to monitor safety. Phase III trials compare the new treatment directly to the current standard of care to determine if it is more effective, equally effective with fewer side effects, or perhaps less effective. Results from these trials guide decisions about whether new treatments should become standard practice.^[2]

Most common treatment methods

• Combination chemotherapy with rituximab
  • R-CHOP regimen combining rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone given in 21-day cycles
  • DA-EPOCH-R regimen using dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab delivered through continuous infusion
  • R-ACVBP combining rituximab with doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone in an intensive schedule
  • Treatment typically involves six cycles over four to six months
• Radiation therapy
  • Mediastinal radiation sometimes used after chemotherapy if disease remains visible on imaging or for very large tumors
  • Modern techniques allow precise targeting to minimize exposure to heart, lungs, and breast tissue
  • Use increasingly questioned due to long-term risks, particularly in young women
  • More intensive chemotherapy regimens may allow many patients to avoid radiation entirely
• Immunotherapy with checkpoint inhibitors
  • Pembrolizumab (Keytruda) blocks PD-1 protein to allow immune system to attack cancer cells
  • Used for relapsed or refractory disease after at least two other treatment approaches
  • Can produce durable responses with generally better tolerability than chemotherapy
  • May cause immune-related side effects such as inflammation of lungs, intestines, or other organs
• CAR T-cell therapy
  • Axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel are genetically modified T cells targeting CD19
  • Patient’s own immune cells are collected, modified in laboratory, grown to large numbers, and infused back
  • Considered for patients who have tried multiple other treatments without success
  • Can cause cytokine release syndrome and neurological effects requiring careful monitoring
• Bispecific antibodies
  • Epcoritamab (Epkinly) and glofitamab (Columvi) connect cancer cells to immune cells
  • Used after two or more prior treatment approaches and if CAR T-cell therapy has failed or is not suitable
  • Engineered proteins with binding sites for both B cells and T cells to facilitate immune destruction
• Stem cell transplantation
  • High-dose chemotherapy followed by autologous stem cell transplant may be used for relapsed disease
  • Patient’s own stem cells are collected before intensive treatment and returned afterward
  • Less successful in PMBCL compared to some other lymphomas, driving research into alternative approaches